HB8763, the TREAT PTSD VA Act, would require the Department of Veterans Affairs to furnish stellate ganglion block treatment to eligible veterans diagnosed with post-traumatic stress disorder. To qualify, a veteran must be enrolled in the VA patient enrollment system, have a PTSD diagnosis, and choose the procedure after being informed of its risks and benefits by a qualified health care provider. The bill allows the VA to provide the treatment either at a VA medical facility or through an authorized community care provider.
The bill also directs the VA to update its PTSD clinical practice guideline within 180 days to reflect stellate ganglion block as a treatment option and to include information on clinical indicators and contraindications. The statutory amendment would take effect 180 days after enactment, giving the department time to prepare implementation and update guidance. In practical terms, the bill would add a new mandatory VA benefit and require corresponding changes to VA clinical policy under title 38 of the U.S. Code.
HB8763 would amend title 38, United States Code, by adding a new section requiring the Secretary of Veterans Affairs to provide stellate ganglion block for certain veterans with PTSD and by updating the chapter 17 table of contents. It would also require the VA to revise its PTSD clinical practice guideline to recognize the therapy and provide clinical guidance, affecting both VA medical operations and community care delivery for eligible veterans.
Based on the available context, the bill appears to have a generally supportive or at least exploratory policy posture, with no recorded votes or committee debate in the provided materials. The measure was introduced and referred to the House Committee on Veterans’ Affairs, suggesting it is still in an early stage of consideration. The framing of the bill emphasizes treatment access, relief, and emerging therapy, indicating a favorable intent toward expanding PTSD care options for veterans.
The main potential point of contention is the requirement that VA furnish a relatively new or emerging procedure, which may raise questions about clinical evidence, safety, implementation standards, and cost. The bill partially addresses this by limiting eligibility to veterans who are informed of the risks and benefits and who elect the treatment, and by requiring the VA to update its clinical guideline with indicators and contraindicators. Another possible issue is whether the treatment should be delivered broadly through VA facilities and community providers or reserved for more limited circumstances, but no specific objections or opposing views are included in the provided record.